AbangeLabsMHRA’s Onkotrone Class 4 notice is a labeling-governance signal, not a new effectiveness finding—still critical for evidence communication.
MHRA issues Class 4 notification for Onkotrone batches after contraception-duration wording gap in patient leaflet
The Medicines and Healthcare products Regulatory Agency published Class 4 Medicines Defect Notification EL(26)A/14 on 17 March 2026 for Onkotrone batches where the included patient leaflet did not reflect updated contraception-duration wording. The agency basis is a labelling-information defect, not a new comparative effectiveness assessment.